British drugmaker AstraZeneca’s cancer drug combination showed a very promising result in the early stage of the study in boosting the immune system in the patients suffering from the fatal disease.
The researchers behind the clinical trial, however, highlighted that the as the study was conducted on a limited number of the patients and the results are preliminary, so, the data is far from conclusive at this stage.
The UK-based drug making company fended off a USD 118 billion takeover bid from another drug maker Pfizer in May this year.
The company has set high hopes over the combination of two experimental drugs called- MEDI4736 and tremelimumab.
The findings of the study from data on only two dozen patients were presented before the European Society for Medical Oncology (ESMO) congress on Saturday.
According to the company, it has detailed only the preliminary findings of the trial that are very promising but is currently exploring a range of doses that is leading to taking more time for the investigators to come up with the final results.
Pascal Soriot, AstraZeneca’s Chief Executive, had also earlier this month confirmed that the numbers presented before the ESMO would be limited.
Researcher Scott Antonia, of Florida’s Moffitt Cancer Center, called the early results very encouraging and promising as far as safety and efficacy is concerned.
AstraZeneca is expecting the final study probe yields more definitive results later this year. It is also mulling over starting a pivotal clinical trial with the drug combination either late this year or at the beginning of 2015.